ReviewJournal of thoracic disease2018
Medical management of bronchiectasis.
Review in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic performance of the FACED score and bronchiectasis severity index in bronchiectasis: a systematic review and meta-analysis.Bioscience reports · 2020Pooled it
- Considerations in the Diagnosis and Management of Bronchiectasis in Older Adults.Clinics in geriatric medicine · 2025Review
- Navigating a Complex Case of Hypoplastic Right Lung With Bronchiectasis: A Ten-Year Journey.Journal of medical cases · 2024Article
- Real-world treatment patterns, health care resource utilization, and costs in a US Medicare population with bronchiectasis.Journal of managed care & specialty pharmacy · 2024Article
- Construction of a panoramic mRNA map of adult noncystic fibrosis bronchiectasis and a preliminary study of the underlying molecular mechanisms.European journal of medical research · 2024Article
- Assessment of factors and interventions towards therapeutic adherence among persons with non-cystic fibrosis bronchiectasis.ERJ open research · 2022Review
- Extracorporeal life support as rescue therapy in severe bronchiectasis with Kartagener's syndrome.Anaesthesiology intensive therapy · 2022Article
- Post-tuberculous lung disease: should we be using Theophylline?Journal of thoracic disease · 2021Review
- ERS International Congress 2020: highlights from the Paediatric Assembly.ERJ open research · 2021Review
- Nocardia colonization in contrast to nocardiosis: a comparison of patients' clinical characteristics.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Bronchiectasis in Primary Antibody Deficiencies: A Multidisciplinary Approach.Frontiers in immunology · 2020Review
- Real-world disease burden, mortality, and healthcare resource utilization associated with bronchiectasis.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The medical management of bronchiectasis includes confirming the diagnosis of the disease, evaluating the patient for possible underlying etiologies and then properly assessing the patient for appropriate therapies. Patients with bronchiectasis are heterogeneous and a personalized approach to each patient is needed in order to properly formulate an optimal management plan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.